CASI Pharmaceuticals

Youtube Subscribe

Open: 2.74 Close: 2.78 Change: 0.04

Can you guess what an AI found about CASI Pharmaceuticals Company Inc.

How much time have you spent trying to decide whether investing in CASI Pharmaceuticals? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about CASI Pharmaceuticals are: …

Concept Map

Semantic Network

Stock Summary

CASI Pharmaceuticals, Inc. develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment.

Today's Summary

CASI Pharmaceuticals (NASDAQ:CASI) Needs To Drive Business Growth Carefully, says Wall St. Simply Wall St. We think CASi Pharmaceuticals needs to drive business growth carefully. CASI has 4 warning signs (and 1 which is a bit concerning) we think you should know about. CASI Pharmaceuticals brought in sales totaling $15.26 million during Q4 according to data provided by Benzinga Pro. CASi Pharmaceuticals now covered by analysts at stocknews.com - defense news. CASI stock opened at $2.45 on Monday.

Today's News

CASI Pharmaceuticals (NASDAQ:CASI) Needs To Drive Business Growth Carefully, says Wall St. Simply Wall St. We think CASi Pharmaceuticals needs to drive business growth carefully. CASI has 4 warning signs (and 1 which is a bit concerning) we think you should know about. CASI Pharmaceuticals brought in sales totaling $15.26 million during Q4 according to data provided by Benzinga Pro. CASi Pharmaceuticals now covered by analysts at stocknews.com - defense news. CASI stock opened at $2.45 on Monday.

Stock Profile

"CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; and CID-103, a human IgG1 anti-CD38 monoclonal antibody. The company has licensing agreements with Juventas Biotechnology (Tianjin) Co., Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China."

Keywords

This document will help you to evaluate CASI Pharmaceuticals without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about CASI Pharmaceuticals are: CASI, Pharmaceuticals, Wall, St, think, CASi, NASDAQCASI, and the most common words in the summary are: therapeutic, pharmaceutical, pharma, night, party, bioscience, casi, . One of the sentences in the summary was: CASI Pharmaceuticals (NASDAQ:CASI) Needs To Drive Business Growth Carefully, says Wall St. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #therapeutic #pharmaceutical #pharma #night #party #bioscience #casi.

Read more →

Youtube Subscribe

---